In a Stackelberg game, a leader commits to a strategy first, and followers respond optimally. In evolutionary game theory, a population of identical agents plays a symmetric game, and the equilibrium is an evolutionarily stable strategy — a strategy that, once adopted by the population, cannot be invaded by mutants. These two frameworks address different questions: Stackelberg is about sequential commitment, ESS is about population stability.
The researchers combine them. A single leader interacts with a large population of followers who play among themselves. The leader commits first; the followers adopt an ESS in the subgame the leader's choice creates. The leader's problem is to choose the commitment that produces the best (for the leader) ESS in the follower population.
The biological application makes the structure concrete. In cancer treatment, the physician is the leader (choosing a treatment protocol), and cancer cell phenotypes are the follower population (evolving in response to the treatment environment). The physician commits to a drug regimen; the cancer cell population evolves to an ESS under that drug pressure. The question is which drug regimen produces the evolutionary endpoint that is best for the patient.
This reframes cancer treatment from a killing problem to a steering problem. The goal is not to eliminate all cancer cells (which selects for resistant phenotypes) but to choose the treatment that makes the evolutionary equilibrium of the remaining population as benign as possible. The physician is not fighting the evolution; the physician is shaping which evolutionary stable state the population reaches.
(arXiv:2603.18385)